Jakavi (ruxolintib)

pCPA File Number: 22021
Negotiation Status:
Concluded with an LOI
Indication(s):
acute graft-versus-host disease
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
SR0688
pCPA Engagement Letter Issued:
Negotiation Process Concluded: